H. Lundbeck A/s Class A · OMXCOP:HLUN_A
H. Lundbeck A/s Class A — Investor Day (2019)
94 slides from H. Lundbeck A/s Class A's investor day presentation, 2019
Slide 1: Lundbeck R&D Event 2019
Lundbeck ZOT9
Slide 2: Company disclaimer
COMPANY DISCLAIMER This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and inaccurate assu
Slide 3: Agenda
LUNDBECK R&D EVENT 2019 Agenda Time (approx.) Min. 13:00-13:30 2 13:30-13:40 10 13:40-14:40 60 14:40-15:05 25 15:05-15:35 30 15:35-16:00 25 16:00-16:50 50 16:50-17:20 30 Topic Coffee, registration Welcome and introduction + Expand and Invest to Grow strategy Lundbeck’s expanding R&D pipeline Eptinez
Slide 4: Presenters
LUNDBECK R&D EVENT 2019 in i K Presenters Presenter Title Deborah Dunsire President & CEO Peter Anastasiou Executive Vice President, North America Morten Grunnet Director, R&D Leadership Office Bjorn Aaris Gronning VP, Clinical Research Neurology Johan Luthman Executive Vice President, R&D Gary O'Ne
Slide 5: Expand and Invest to Grow
LUNDBECK R&D EVENT 2019 Speaker: Dr. Deborah Dunsire Expand and Invest to Grow
Slide 6: The Expand and Invest to Grow strategy plan
EXPAND AND INVEST TO GROW The Expand and Invest to Grow strategy plan (wom 1 se, MAXIMIZE exPAN OPERATING { EXISTING BRANDS ] SPACE a ( _\ and Invest | fo > x FOCUS ON | to Grow | \ ee } [REBUILD PIPELINE) \ ) <x — ORGANI- | ZATIONAL \ AGILITYAND \ COLLABO- / Nea | Makea | difference \ for patients
Slide 7: We maximize growth opportunities in our current business
EXPAND AND INVEST TO GROW We maximize growth opportunities in our current business and maintain a disciplined approach to cost We maximize the We enhance performance of organizational agility existing brands and collaboration Ax Abilify Maintena We expand our global ——— footprint We continue to ” ma
Slide 8: We maximize our existing brands
EXPAND AND INVEST TO GROW 1 neh Through excellent execution, together with targeted x acceleration projects, we maximize our existing brands Strategic Brands Mature Brands +29% Unchanged abril, X Been 7 Cipramil® BG ture brai Ae = Ebixa aia eit ff tegic B Cipralex Trntell egic Br as We ale? x Brinte
Slide 9: Expand and Invest to Grow has expanded our operational space
EXPAND AND INVEST TO GROW Expand and Invest to Grow has expanded our operational space | Makea and Invest | difference | to Grow for patients Guided by Lundbeck’s Purpose: Tirelessly dedicated to restoring brain health, so every person can be their best Drive \ business | results “ALDER BIOPHARMACEU
Slide 10: Projects included in R&D pipeline in February 2019
EXPAND AND INVEST TO GROW Expand and Invest to Grow - 11 projects included in our R&D pipeline in February 2019 Project Indication Brexpiprazole Bipolar mania Brexpiprazole Agitation in Alzheimer’s disease Brexpiprazole PTSD Foliglurax (mGluR4 PAM) Parkinson's disease Lu AF11167 (PDE 10 inhibitor) S
Slide 11: 15 projects included in R&D pipeline in November 2019
EXPAND AND INVEST TO GROW 1 neh K Expand and Invest to Grow - 15 projects included in our R&D pipeline in November 2019 Project Eptinezumab (ant+CGRP mAb) Eptinezumab (anti-CGRP mAb) Brexpiprazole Brexpiprazole Brexpiprazole Foliglurax (mGluR4 PAM) Lu AF11167 (PDE 10 inhibitor) Lu AG06466 (MGLLi) Ab
Slide 12: Expanding the R&D pipeline
Expanding the R&D pipeline
Slide 13: Expand and Invest to Grow has significantly strengthened the pipeline
EXPANDING THE R&D PIPELINE 1 neh K Expand and Invest to Grow has significantly strengthened the pipeline Project Eptinezumab (anti-CGRP mAb) Eptinezumab (ant+CGRP mAb) Brexpiprazole Brexpiprazole Brexpiprazole Indication/label expansion Migraine prevention "Treat and Prevent’, migraine Agitation in
Slide 14: Focus on translational research
EXPANDING THE R&D PIPELINE Isa K We focus on translational research to bridge the gap between pre-clinical and clinical research The human brain has complexity and Translation at behavioural level 5 5 © proofs difficult for existing executive functions that are not f Cognition assays and tests ee re
Slide 15: Long-term vision: Transformative neuroscience
EXPANDING THE R&D PIPELINE Long-term vision: Transformative neuroscience Reduce attrition . rates in R&D by... Focus on biomarkers and experimental medicine Projects enter development only with clear biomarker strategy Projects enter clinical phase III only after solid supportive Proof of Concept ”L
Slide 16: Simplifying the organization to drive operational excellence
R&D IN LUNDBECK Lats OE We are simplifying the organization to drive operational excellence Simplified Global R&D Cross-functional Decision Making Organization Portfolio Management Board Special emphasis on... established to increase research, development and commercial alignment on all programs Est
Slide 17: Pivotal programmes
x Pivotal programmes Phase III
Slide 18: Phase III: Brexpiprazole – Agitation in Alzheimer's
PHASE III Restoring brain health Brexpiprazole — Agitation in Alzheimer’s
Slide 19: Brexpiprazole in agitation in Alzheimer's disease
BREXPIPRAZOLE Brexpiprazole in pivotal programme for the treatment of agitation in Alzheimer’s disease Alzheimer’s Disease (AD) 50 million people worldwide have dementia (Alzheimer's is the most common cause of dementia contributing 60-70% of cases) It is predicted that the number of people affected
Slide 20: Brexpiprazole fixed-dose study
BREXPIPRAZOLE Grossberg: “Efficacy and safety of fixed-dose brexpiprazole for the treatment of agitation in Alzheimer’s type dementia” (AAGP2018) CMAI: Brexpiprazole 2mg/day statistically significant improvement over placebo CGI-S score”): Numerical improvement was observed for brexpiprazole 2 mg/da
Slide 21: Brexpiprazole flexibly-dosed study
BREXPIPRAZOLE Cummings: “Efficacy and safety of flexibly-dosed brexpiprazole for the treatment of agitation in Alzheimer’s type dementia” (aacp2018) CMAI: Numerically favourable for flexibly- dosed brexpiprazole (0.5-2 mg/day) over placebo, but Post-hoc analysis —subgroup of patients titrated to 2mg
Slide 22: Third study in pivotal programme progresses
BREXPIPRAZOLE Third study in brexpiprazole pivotal programme in Agitation in Alzheimer’s progresses as planned Study objective! To compare the efficacy of 2 doses of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type (n = ~225) 1. Clinicaltrials go
Slide 23: Phase III: Brexpiprazole – PTSD
PHASE III Restoring brain health Brexpiprazole — Post-Traumatic Stress Disorder (PTSD)
Slide 24: PTSD offers an opportunity for brexpiprazole
BREXPIPRAZOLE PTSD offers an exciting opportunity for brexpiprazole PTSD epidemiology >8m-U.S. prevalence (2.5%-3.6%)" 2 ~3m-— Severe (36.6%) 2 ~1.8m — pharmacological treatment rate (~60%)? Post-traumatic Stress Disorder (PTSD) ~8.6m U.S. adults affected, but ~80% estimated to be undiagnosed Growin
Slide 25: Both PTSD pivotal studies commenced
BREXPIPRAZOLE Both studies in brexpiprazole pivotal Leadbeh K programme in PTSD commenced Study objective! To evaluate the efficacy, safety, and tolerability of 12-week brexpiprazole + sertraline combination treatment in adult subjects with PTSD (n = ~600) 1. Clinicaltrials.gov ID: NCTO4124614 Two s
Slide 26: Proof of Concept Phase II
Proof of Concept Phase II
Slide 27: Brexpiprazole – Borderline Personality Disorder
el Lass JK Restoring brain health Brexpiprazole — Borderline Personality Disorder (BPD)
Slide 28: BPD offers an opportunity for brexpiprazole
BREXPIPRAZOLE Borderline Personality Disorder (BPD) offers an Leadbeh K exciting opportunity for brexpiprazole BPD epidemiology ~5m-U.S. prevalence (1.6%, but likely higher)” ~2.4m - diagnosis rate (45%) ~1.7m— pharmacological treatment rate (~70%)?) Borderline Personality Disorder (BPD) Dysfunction
Slide 29: Brexpiprazole PoC study in BPD commenced
BREXPIPRAZOLE Brexpiprazole PoC study in Borderline Personality Disorder (BPD) commenced Study objective! To evaluate the efficacy and safety of 12-week brexpiprazole for the treatment of subjects diagnosed with BPD (n = ~240) to provide a pharmacological treatment for BPD 1. Clnicaltrials.gov ID: N
Slide 30: Phase II: Lu AF11167
PHASE II Restoring brain health Lu AF11167
Slide 31: Negative symptoms represent a major unmet medical need
LU AF11167 Negative symptoms represent a major unmet medical need Schizophrenia has three core symptoms: Positive, cognitive and negative symptoms Negative symptoms together with impaired cognition are the major cause of the marked functional disability Negative symptoms are thus a key contributor t
Slide 32: PDE10 inhibition: a new approach
LU AF11167 PDE10 inhibition: A new approach to obtain a combined D, agonist-like effect and D, antagonist-like effect . D, Receptor Stimulator Inhibitor Vie, | \ se t wy, D, receptors D, receptors are stimulatory GPCRs Dopamine at the D, receptor stimulates adenylate cyclase and increases CAMP By bl
Slide 33: Proof-of-concept study commenced in December 2018
LU AF11167 1 neh K Proof-of-concept study commenced in December 2018 Monotherapy* . . . Screening] Screening2 Baseline Completion Two fixed-flexible doses, once daily 1-2mg/day Clinically stable patients on antipsychotic 3-4mg/day AF 11167 flex-flexible low dose placebo eee n=80 N = ~250 patients AF
Slide 34: Phase II: Foliglurax
PHASE II Restoring brain health Foliglurax
Slide 35: Foliglurax: potential new treatment for Parkinson's
FOLIGLURAX Lats OE Foliglurax is a potential new treatment for Parkinson’s disease PD-LID is the most important unmet medical need after disease modification in Parkinson's") PD-LID affects ~50% after 5-10 years increasing to ~90% after 10-15 years of L- DOPA therapy 170-200,000 patients in the U.S.
Slide 36: Phase IIa AMBLED study near final recruitment
FOLIGLURAX Phase Ila study (AMBLED) investigating foliglurax near final recruitment Study objective! Evaluate the efficacy, safety and tolerability of 28-Day oral treatment with foliglurax in reducing motor complications of levodopa therapy in subjects with Parkinson's disease experiencing end-of-do
Slide 37: Early projects
LUNDBECK R&D EVENT 2019 Speaker: Morten Grunnet Karly projects
Slide 38: Lu AF82422: potential disease modifying antibody
EARLY PROJECTS Lu AF82422: Potential disease modifying antibody for Parkinson’s disease Pathological alpha-synuclein is released to extracellular space upon cell death and can mediate seeding and aggregation of alpha-synuclein in healthy neurons! This process is considered to be central in the disea
Slide 39: Lu AF28996: potential oral treatment for Parkinson's
EARLY PROJECTS Lu AF 28996: A potentially new oral treatment for Leadbeh K Parkinson’s patients experiencing motor fluctuations D,/D.-type agonists Known to be highly efficacious even in the later stages of Parkinson's, but the currently available agonist (apomorphine) cannot be delivered by oral ro
Slide 40: Lu AG09222 PACAP antibody
• • • 1) Loomis et al: Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide, JPET Fast Forward 2) Pituitary adenylate cyclase-activating peptide 3) Calcitonin gene-related peptide
Slide 41: Lu AF88434: potential to improve cognition
EARLY PROJECTS Lu AF88434: Potential to improve cognition Phosphodiesterase 1 (PDE] PDE1 is an intracellular enzyme responsible for the degradation of cGMP and cAMP cGMP is a critical intracellular signalling molecule that regulates neuronal functions like synaptic plasticity, cognitive function, ne
Slide 42: Lu AF87908: potential for delaying Alzheimer's progression
EARLY PROJECTS Lu AF87908 — Potential for delaying disease progression in Alzheimer’s or other tauopathies + LuAF87908 is a humanized lgG1 mAb recognizing Tau Competitive advantage by * Binding to and inhibition of pathological seeding form of Tau * Specific and pathology directed mAb + Retaining th
Slide 43: Lu AG06466 (former ABX-1431)
PHASE II Speaker: Gary O'Neill Lu AG06466 former ABX-1431
Slide 44: Serine hydrolases: a rich source of new medicines
LU AGO6466 Serine hydrolases: A rich source of diverse new medicines A large enzyme family (~250) Diverse substrates Proteins, peptides, lipids, etc Diverse functions CNS signalling, inflammation, metabolism Common catalytic mechanism Active-site serine residue for catalysis Lundbeck La Jolla Resear
Slide 45: Endocannabinoid augmentation as a therapeutic strategy
LU AGO6466 Leadbeh K Endocannabinoid augmentation as a therapeutic strategy Two main endogenous cannabinoid ligands: FAAH inhibition MGLL inhibition Anandamide (or AEA) and 2- ‘Potentiation of AEA signalling’ ‘Potentiation of 2-AG signalling’ Arachidonylglycerol (or 2-AG) VO. CDOS: MGLL inhibition l
Slide 46: MGLL is a fundamental regulator of neurotransmission
LU AGO6466 Leadbeh K MGLL is a fundamental regulator of neurotransmission Endocannabinoid signalling limits excessive neurotransmission MGLL inhibition amplifies retrograde endocannabinoid signalling and rectifies overactive synapses Restoration of balanced Endocannabinoids (such neurotransmission b
Slide 47: MGLL inhibitors may benefit many conditions
LU AGO6466 MGLL inhibitors may benefit many conditions Traumatic Brain Injury Stroke Haemorrhagic Stroke Treatment Resistant Epilepsy Epilepsy Syndromes MOVEMENT DISORDERS PSYCHIATRIC CONDITIONS Leadbeh K Tourette Syndrome Huntington’s Disease Parkinson’s Disease MS Spasticity Neuropathic Pain Centr
Slide 48: MGLL inhibitor portfolio
LU AGO6466 MGLL inhibitor portfolio: Harnessing the therapeutic potential of the endocannabinoid system Access to world class MGLL development candidates to bolster the portfolio Pipeline in a drug — many potential indications Discovery site in U.S. World class platform to address novel biological t
Slide 49: Differentiation from exocannabinoids
LU AGO6466 Lu AG06466 differentiation from exocannabinoids Endocannabinoid system regulates Endocannabinoid signaling is triggered in neurotransmission throughout the brain hyperactive circuits % &@ Synthetic/exogenous agonists (e.g. THC) MGLL inhibition amplifies endocannabinoid ‘activate cannabino
Slide 50: Being tested in Tourette Syndrome
LU AGO6466 Lu AG06466: Being tested in Tourette Syndrome (TS) Modulates the endocannabinoid system preferentially in areas where neuronal circuits are excessively activated Initial trials ongoing in TS’s and neuropathic pain Phase Ib trial”) in adult TS patients (n = 23) demonstrated significant eff
Slide 51: Phase IIa study near finalization
Lu AG06466 Phase IIa study investigating Lu AG06466 near finalization Study objective! This study will assess the safety, tolerability, and effect on tics Lu AG06466 (previously ABX-1431) in adults with Tourette Syndrome or chronic motor tic disorder in an 8- week study. It is a two-part study Part
Slide 52: Phase Ib study in neuropathic pain
LU AG06466 Lu AG06466 in phase Ib safety and tolerability study in neuropathic pain MGLLi have shown to reduce pain in preclinical models of inflammatory, post-surgical, and neuropathic pain Significant scientific evidence supports the use of exocannabinoids for the treatment of pain, including cont
Slide 53: Eptinezumab
LUNDBECK R&D EVENT 2019 Speaker: Bjarn Aaris Granning Eptinezumab
Slide 54: Migraine is one of the most debilitating diseases globally
EPTINEZUMAB Migraine is one of the most debilitating diseases globally ~18m ~18m individuals are candidates for prevention <50% ~ less than 50% are treated* 4-72 hours Attacks usually last 4-72 hours” Most disabling disease for people under 50 years - the most productive years of people’s lives! Sym
Slide 55: Migraine profoundly affects patients' lives
EPTINEZUMAB Migraine profoundly affects patients’ lives 93% say migraine affects their ability to work! 89% say migraine affects their ability to maintain relationships with a partner! 86% say migraine affects their ability to maintain relationships with children! 4/10 Only 4/10 are satisfied with t
Slide 56: Migraine prevention is a large and underserved market
EPTINEZUMAB Migraine prevention represents a large and under served market Addressable population (major countries!) ~134m - Migraine prevalence ~41m-— diagnosed patients (30%) ~18m - Eligible for prevention (43%) ~9m - Currently on prophylactic treatment 1) Decision Resource, DRG 2018 Migraine Mark
Slide 57: Rapid, effective and sustained elimination of CGRP
EPTINEZUMAB Lndbedh K Eptinezumab: Rapid, effective and sustained elimination of calcitonin gene-related peptide (CGRP) * Humanized, IgG1, anti CGRP monoclonal antibody! * Selectively and potently inhibits CGRP biological activity + 5 pM binding affinity for CGRP * Persistent molecular activity (t 1
Slide 58: Two large pivotal studies demonstrated sustained efficacy
EPTINEZUMAB Leadbeh K Two large pivotal studies including ~2,000 patients demonstrated sustained efficacy and good tolerability Promise | Promise 2 Power! 250%, 275% and | | in Episodic Migraine Patients in Chronic Migraine Patients oon reductions in migraine (N=888; baseline ~9 migraine days/month)
Slide 59: Promise 1: episodic migraine
EPTINEZUMAB Leadbeh K Promise |: A phase ITI study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraine ¢ Eptinezumab reaching statistical significance for the primary and all ee key secondary endpoints 80 __ 900167 * Migraine day prevalence dropped 35 5 =
Slide 60: Promise 2: reductions from Day 1 in chronic migraine
EPTINEZUMAB Eptinezumab achieved meaningful reductions in migraine activity as early as Day | that were sustained through Week 12: results from Promise-2 phase ITI trial in chronic migraine * Insubjects with chronic migraine beginning on the Ist day post- infusion, a single infusion of eptinezumab s
Slide 61: Significant reduction in monthly migraine days
EPTINEZUMAB Leadbeh K Significant reduction in monthly migraine days (MMDs) with eptinezumab at both 100mg and 300 mg . . Promise-] Promise-2 Eptinezumab has shown high (Change from baseline in MMDs) (Change from baseline in MMDs) response rates, especially in adult patients experiencing frequent, c
Slide 62: HIT-6 patient-reported outcome
EPTINEZUMAB 1 neh K HIT-6 is a widely used patient-reported outcome measure in headache and migraine research * General measure of impact of headache on daily life’ * Six-item scale (severe pain, limits daily activities, lie down, too tired, felt fed up or irritated, limits concentration)! 78 PROMIS
Slide 63: Eptinezumab well-tolerated across doses
EPTINEZUMAB Leadbeh K Eptinezumab treatment well-tolerated across doses as compared to placebo Safety and tolerability were evaluated in the Promise | and Promise 2 trials In pooled data assessment across the two trials, nasopharyngitis (swelling of the nasal passages and the back of the throat) was
Slide 64: Powerful, fast and sustained action
EPTINEZUMAB Sunde Eptinezumab — Powerful, Fast and Sustained action Eptinezumab promise * Rapid onset of prevention by Day 1 driven by IV formulation and 100% bioavailability, addressing unmet medical need Strong response rate data from two phase III studies Strong impact on patient's response on Qu
Slide 65: Upcoming newsflow with life cycle management potential
EPTINEZUMAB Eptinezumab — Exciting upcoming newsflow with interesting LCM potential Regulatory: U.S. PDUFA action date: 21 February 2020 Expected submission in Canada (Q1 2020), EU (by end 2020), followed by submissions for approval in other regions around the world Ongoing studies: RELIEF study sta
Slide 66: Preparing to launch eptinezumab
LUNDBECK R&D EVENT 2019 Speaker: Peter Anastasiou - Executive Vice President, North America Preparing to launch eptinezumab
Slide 67: Eptinezumab: Poised for success
PREPARING TO LAUNCH EPTINEZUMAB Eptinezumab: Poised for success Why Lundbeck is well positioned to successfully launch eptinezumab in the US. 2 Despite recent entrants, the migraine market still has substantial unmet need 3 Eptinezumab’s fast, powerful and sustained control in prevention of migraine
Slide 68: US launch success with 7 products in 10 years
PREPARING TO LAUNCH EPTINEZUMAB 1 neh K Lundbeck U.S. launch success with 7 products in 10 years Diversity of indications with customized formulations a Speed to market ee ‘Maintenance monotherapy for bipolar lapproved Track record of trusted relationships 2019 1 . . E H Value creation through life
Slide 69: Eptinezumab will benefit from Lundbeck's capabilities
PREPARING TO LAUNCH EPTINEZUMAB Ile Eptinezumab will benefit from Lundbeck’s capabilities x Orphan/Specialty Distribution Xenazine, Sabril, Northera, Onfi, Abilify Maintena Limited patient population Limited number of physicians + Fewer competitors * Low SG&A requirements * Specialty pharmacy distri
Slide 70: Patient-centricity and corporate reputation
Lats OE Patient-centricity Transparency in Lundbeck } funding k d Patient information ranke Corporate integrity Patient safety Quality of patient- High-quality products group relationships Transparency in “beyond the pill” by patient groups four years in a row pricing services PatientView Corporate
Slide 71: US organization redesigned to maximize strategic brands
PREPARING TO LAUNCH EPTINEZUMAB The U.S. organization has been redesigned to maximize strategic brands while leveraging synergies and reputation in neurology Peter Anastasiou EVP, North America { US Chief Commercial Officer | { 1 Psychiatry Business Unit Neurology Business Unit As Bg w a Aoubvemes G
Slide 72: Eptinezumab: Poised for success
PREPARING TO LAUNCH EPTINEZUMAB Eptinezumab: Poised for success 1 Why Lundbeck is well positioned to successfully launch eptinezumab in the US. Despite recent entrants, the migraine market still has substantial unmet need 3 Eptinezumab’s fast, powerful and sustained control in prevention of migraine
Slide 73: Patients are dissatisfied with previous treatments
PREPARING TO LAUNCH EPTINEZUMAB 1 neh K Patients are dissatisfied with previous treatments based on tolerability and lack of sustained efficacy Oral Up to 80% preventives fail discontinue to meet needs of many patients: use of oral preventives within 6- adherence, safety, tolerability 12 months due
Slide 74: Dissatisfied patients will expand the market potential
PREPARING TO LAUNCH EPTINEZUMAB a of Patients dissatisfied with first generation prevention options will expand the market potential Migraine prevention market: 13.9m!? Breakout of 27% treated group Preventive Treatments % of Use® Botox 10% CGRP 5% 12018 DRG Migraine Market Landscape & Forecast, 320
Slide 75: Prevention market growing, driven by CGRP class
PREPARING TO LAUNCH EPTINEZUMAB 1 neh K The overall prevention market is growing primarily driven by CGRP class Anti-Migraine 2.000.000 Market 5% increase in last quarter vs Q2 2019 1.500.000 1.000.000 500.000 CGRPs 250.000 21% increase in last quarter vs Q2 2019 200.000 150.000 100.000 50.000 0 Apr
Slide 76: Commoditization of S.C. CGRPs provides room for differentiation
PREPARING TO LAUNCH EPTINEZUMAB 1 neh K The commoditization of the S.C. CGRPs provides room for differentiation with eptinezumab Similar launch timing Minimally A commoditized and product differentiated launch marketplace BOTOX has been attributes execution largely unaffected by 82% of HCPs? view cu
Slide 77: Eptinezumab: Poised for success
PREPARING TO LAUNCH EPTINEZUMAB Eptinezumab: Poised for success 1 Why Lundbeck is well positioned to successfully launch eptinezumab in the US. 2 Despite recent entrants, the migraine market still has substantial unmet need Eptinezumab’s fast, powerful and sustained control in prevention of migraine
Slide 78: A specifically designed antibody targeting the CGRP ligand
PREPARING TO LAUNCH EPTINEZUMAB 1 neh K Eptinezumab: A specifically designed antibody targeting the CGRP ligand Selective binding Strong binding Immediate availability High specificity for CGRP ligand! High affinity for CGRP ligand’ 100% bioavailability for rapid exposure! Eptinezumab design feature
Slide 79: Fast, effective and sustained elimination of CGRP
PREPARING TO LAUNCH EPTINEZUMAB 1 neh Eptinezumab: fast, effective and sustained elimination x of CGRP! that delivers meaningful patient outcomes Onset of prevention starting from Day 1 Fast post- 30 min IV administration; >50% of Onset of preventi patients have no migraine 1 day post infusion Day O
Slide 80: Eptinezumab: Poised for success
PREPARING TO LAUNCH EPTINEZUMAB Eptinezumab: Poised for success 1 2 Why Lundbeck is Despite recent well positioned to entrants, the successfully launch migraine market still eptinezumab in the has substantial unmet US. need 3 Eptinezumab’s fast, powerful and sustained control in prevention of migrai
Slide 81: Additional factors allow eptinezumab to differentiate
PREPARING TO LAUNCH EPTINEZUMAB Many additional factors allow for eptinezumab to differentiate in the market Physicians Epti product profile show great acceptance and willingness to prescribe Patients Patients are suffering and need preventive medications that work, and work faster Specialis Custome
Slide 82: Physicians prefer greater control over total patient care
Slide 83: Empower the right patients to ask for eptinezumab
Slide 84: ~650 accounts driving 50% of migraine prevention volume
Slide 85: Medical vs. pharmacy benefit dynamic
Slide 86: Setting expectations: short-term challenge exists
Slide 87: Data for physician administered products less transparent
Slide 88: Global reach
Slide 89: Wheels are in motion for global roll-out
Slide 90: Eptinezumab: Poised for success – In summary
Slide 91: What makes migraine unique?
Slide 92: Migraine
Slide 93: ►
►
Slide 94: Thank you!